4,4′-Bis(2-Bromoacetyl)biphenyl CAS 4072-67-7 Daclatasvir Dihydrochloride Intermediate Purity >98.0% (HPLC)

Short Description:

Chemical Name: 4,4′-Bis(2-Bromoacetyl)biphenyl

CAS: 4072-67-7

Purity: >98.0% (HPLC)   

Intermediate of Daclatasvir Dihydrochloride CAS 1009119-65-6

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

4072-67-7 - Description:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of 4,4'-Bis(2-Bromoacetyl)biphenyl (CAS: 4072-67-7) with high quality. Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase 4,4'-Bis(2-Bromoacetyl)biphenyl, Please contact: alvin@ruifuchem.com

4072-67-7 - Chemical Properties:

Chemical Name 4,4'-Bis(2-Bromoacetyl)biphenyl 
Synonyms 4,4'-Bis(Bromoacetyl)biphenyl; 1,1'-[1,1'-Biphenyl]-4,4'-diylbis[2-Bromoethan-1-one]; Daclatasvir Impurity 7
Stock Status In Stock, Commercial Production  
CAS Number 4072-67-7 
Molecular Formula C16H12Br2O2
Molecular Weight 396.07 g/mol
Melting Point 226.0~227.0℃ 
Density 1.622±0.06 g/cm3 
COA & MSDS Available
Origin Shanghai, China
Category   Intermediate of Daclatasvir Dihydrochloride (CAS: 1009119-65-6) 
Brand Ruifu Chemical

4072-67-7 - Specifications:

Items Specifications  Results
Appearance Solid   Solid  
Purity / Analysis Method >98.0% (HPLC)  98.5% 
Infrared Spectrum Consistent with Structure Complies 
1H NMR Spectrum Consistent with Structure Complies
Conclusion The product has been tested and complies with the given specifications
Application Intermediate of Daclatasvir Dihydrochloride (CAS: 1009119-65-6)

Package/Storage/Shipping:

Package: Fluorinated Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry and well-ventilated warehouse away from incompatible substances. Protect from light and moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery. 

Advantages:

Sufficient Capacity: Sufficient facilities and technicians

Professional Service: One stop purchasing service

OEM Package: Custom package and label available

Fast Delivery: If within stock, three days delivery guaranteed

Stable Supply: Maintain reasonable stock    

Technical Support: Technology solution available

Custom Synthesis Service: Ranged from grams to kilos

High Quality: Established a complete quality assurance system

FAQ:

How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com 

15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.

Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.

Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.

Quality AssuranceStrict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.

SamplesMost products provide free samples for quality evaluation, shipping cost should be paid by customers.

Factory AuditFactory audit welcome. Please make an appointment in advance.

MOQ? No MOQ. Small order is acceptable.

Delivery Time? If within stock, three days delivery guaranteed.

TransportationBy Express (FedEx, DHL), by Air, by Sea.

Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.

Custom SynthesisCan provide custom synthesis services to best fit your research needs.

Payment TermsProforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc. 

4072-67-7 - Application:

4,4'-Bis(2-Bromoacetyl)biphenyl (CAS: 4072-67-7) is an intermediate of Daclatasvir Dihydrochloride (CAS: 1009119-65-6).
Daclatasvir Dihydrochloride (Daklinza ) is an inhibitor of hepatitis C virus (HCV) NS5A that is useful in the treatment of genotype 3 chronic hepatitis C infection.
On July 24, 2015, the FDA approved the chronic hepatitis C drug (Bristol-Myers Squibb) for marketing.
The FDA approval process of Daklinza (Bristol-Myers Squibb) has undergone twists and turns. It has been once rejected by the FDA, but finally approved in mid-2015. The FDA approved the combination of Daklinza and Sofosbuvir for the treatment of hepatitis C gene type 3 patients.
In fact, as early as before the FDA approval, Daklinza had been approved for marketing in Japan, the European Union and South Korea and other countries. In 2014, Japanese health sector approved the application of Daklinza and Asunaprevir (Sunvepra) for the treatment of genotype 1 infection. The European Union also approved Daclatasvir to be used in combination with other drugs in the treatment of HCV genotypes 1, 2, 3 and 4 in 2014. Daclatasvir is the first NS5A complex inhibitor approved by European Union (EU). When used in combination with other drugs, compared with the treatment combination of interferon and ribavirin which takes 48 weeks, it has a shorter duration of treatment (12 weeks or 24 weeks).
Daclathavir monotherapy is not recommended, the current mainstream protocol is combination therapy of Dacastavir+ Sofosbuvir, which is characterized by good efficacy, higher SVR, small side effects and further shortened treatment cycle than other options.   

  • Write your message here and send it to us